Competition to hot up as Medtronic nears EU launch of DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
In what will represent its debut in the drug-eluting stent (DES) market, Medtronic is anticipating a European launch of its Endeavor device this spring. The company says it remains on track with plans to CE-mark the ABT-578-eluting stent and is prepared for an "aggressive market launch", writes Neena Brizmohun.